Pamlectabart is a humanised antibody targeting TNFRSF17/BCMA, which can be used to synthesise the antibody-drug conjugate (ADC) Pamlectabart tismanitin for the study of multiple myeloma.
Purity:
96.60%
Target:
TNF
* VAT and and shipping costs not included. Errors and price changes excepted
